Cambrex (CBM) Tops Q1 EPS by 7c; Comments on Outlook

May 5, 2009 5:09 PM EDT

Cambrex (NYSE: CBM) reports Q1 EPS of $0.16, 7 cents better than the analyst estimate of $0.09. Revenue for the quarter was $61.03 million, versus the consensus of $59.80 million.

The Company continues to expect that sales, net of the impact of foreign currency, will increase between 2% and 6% in 2009 compared to 2008, and that Adjusted EBITDA will be between $42 and $49 million. Adjusted EBITDA for guidance purposes excludes the impact of any potential M&A, restructuring, or strategic alternatives expenses. Considering the current macro-economic environment, the Company continues to believe that there is a high level of uncertainty regarding sales and profit forecasts for 2009, especially as it pertains to the Company's custom development sales to support our customers' clinical trials.

For 2009, capital expenditures are expected to be approximately $13 to $16 million and depreciation is expected to be $20 to $22 million. The Company currently expects restructuring and strategic alternatives expenses for 2009 to be minimal.

Related Categories

Earnings

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?